APO Research
Talk to an analyst

APO RESEARCH · REPORT

Genetic Disorders Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Genetic Disorders Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025180 pages

Choose your research edition.

Industry ResearchGenetic Disorders Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetic Disorders Drug Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Genetic Disorders Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetic Disorders Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetic Disorders Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Genetic Disorders Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Genetic Disorders Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Genetic Disorders Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Genetic Disorders Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Genetic Disorders Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Genetic Disorders Drug include Takeda, Sanofi, Pfizer, Amgen, Vertex, Sarepta, GW Pharmaceuticals and BioMarin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Genetic Disorders Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Genetic Disorders Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Genetic Disorders Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Genetic Disorders Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Genetic Disorders Drug Segment by Company

Takeda

Sanofi

Pfizer

Amgen

Vertex

Sarepta

GW Pharmaceuticals

BioMarin

Genetic Disorders Drug Segment by Type

Duchenne Muscular Dystrophy (DMD)

Cystic Fibrosis (CF)

Lysosomal Storage Disease (LSD)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Genetic Disorders Drug Segment by Application

Clinic

Hospital

Genetic Disorders Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Disorders Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetic Disorders Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Disorders Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Genetic Disorders Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Genetic Disorders Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Genetic Disorders Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Genetic Disorders Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Genetic Disorders Drug Industry Trends Table 2. Genetic Disorders Drug Industry Drivers Table 3. Genetic Disorders Drug Industry Opportunities and Challenges Table 4. Genetic Disorders Drug Industry Restraints Table 5. Global Genetic Disorders Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Genetic Disorders Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Genetic Disorders Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Genetic Disorders Drug Sales Market Share by Manufacturers Table 9. Global Genetic Disorders Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Genetic Disorders Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Genetic Disorders Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Genetic Disorders Drug Manufacturers, Product Type & Application Table 13. Global Genetic Disorders Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Genetic Disorders Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Duchenne Muscular Dystrophy (DMD) Table 17. Major Manufacturers of Cystic Fibrosis (CF) Table 18. Major Manufacturers of Lysosomal Storage Disease (LSD) Table 19. Major Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Table 20. Global Genetic Disorders Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Genetic Disorders Drug Sales by Type (2021-2026) & (W Units) Table 22. Global Genetic Disorders Drug Sales by Type (2027-2032) & (W Units) Table 23. Global Genetic Disorders Drug Sales Market Share by Type (2021-2026) Table 24. Global Genetic Disorders Drug Sales Market Share by Type (2027-2032) Table 25. Global Genetic Disorders Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Genetic Disorders Drug Revenue by Type (2021-2026) & (W Units) Table 27. Global Genetic Disorders Drug Revenue by Type (2027-2032) & (W Units) Table 28. Global Genetic Disorders Drug Revenue Market Share by Type (2021-2026) Table 29. Global Genetic Disorders Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Hospital Table 32. Global Genetic Disorders Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Genetic Disorders Drug Sales by Application (2021-2026) & (W Units) Table 34. Global Genetic Disorders Drug Sales by Application (2027-2032) & (W Units) Table 35. Global Genetic Disorders Drug Sales Market Share by Application (2021-2026) Table 36. Global Genetic Disorders Drug Sales Market Share by Application (2027-2032) Table 37. Global Genetic Disorders Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Genetic Disorders Drug Revenue by Application (2021-2026) & (W Units) Table 39. Global Genetic Disorders Drug Revenue by Application (2027-2032) & (W Units) Table 40. Global Genetic Disorders Drug Revenue Market Share by Application (2021-2026) Table 41. Global Genetic Disorders Drug Revenue Market Share by Application (2027-2032) Table 42. Global Genetic Disorders Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Genetic Disorders Drug Sales by Region (2021-2026) & (W Units) Table 44. Global Genetic Disorders Drug Sales Market Share by Region (2021-2026) Table 45. Global Genetic Disorders Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 46. Global Genetic Disorders Drug Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Genetic Disorders Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 48. North America Genetic Disorders Drug Sales by Country (2021-2026) & (W Units) Table 49. North America Genetic Disorders Drug Sales by Country (2027-2032) & (W Units) Table 50. Europe Genetic Disorders Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. Europe Genetic Disorders Drug Sales by Country (2021-2026) & (W Units) Table 52. Europe Genetic Disorders Drug Sales by Country (2027-2032) & (W Units) Table 53. Asia Pacific Genetic Disorders Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Asia Pacific Genetic Disorders Drug Sales by Country (2021-2026) & (W Units) Table 55. Asia Pacific Genetic Disorders Drug Sales by Country (2027-2032) & (W Units) Table 56. South America, Middle East and Africa Genetic Disorders Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. South America, Middle East and Africa Genetic Disorders Drug Sales by Country (2021-2026) & (W Units) Table 58. South America, Middle East and Africa Genetic Disorders Drug Sales by Country (2027-2032) & (W Units) Table 59. Global Genetic Disorders Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Genetic Disorders Drug Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Genetic Disorders Drug Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Genetic Disorders Drug Revenue Market Share by Region (2021-2026) Table 63. Global Genetic Disorders Drug Revenue Market Share by Region (2027-2032) Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Genetic Disorders Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Takeda Genetic Disorders Drug Product Portfolio Table 68. Takeda Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Genetic Disorders Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi Genetic Disorders Drug Product Portfolio Table 73. Sanofi Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Genetic Disorders Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Genetic Disorders Drug Product Portfolio Table 78. Pfizer Recent Development Table 79. Amgen Company Information Table 80. Amgen Business Overview Table 81. Amgen Genetic Disorders Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Amgen Genetic Disorders Drug Product Portfolio Table 83. Amgen Recent Development Table 84. Vertex Company Information Table 85. Vertex Business Overview Table 86. Vertex Genetic Disorders Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Vertex Genetic Disorders Drug Product Portfolio Table 88. Vertex Recent Development Table 89. Sarepta Company Information Table 90. Sarepta Business Overview Table 91. Sarepta Genetic Disorders Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sarepta Genetic Disorders Drug Product Portfolio Table 93. Sarepta Recent Development Table 94. GW Pharmaceuticals Company Information Table 95. GW Pharmaceuticals Business Overview Table 96. GW Pharmaceuticals Genetic Disorders Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. GW Pharmaceuticals Genetic Disorders Drug Product Portfolio Table 98. GW Pharmaceuticals Recent Development Table 99. BioMarin Company Information Table 100. BioMarin Business Overview Table 101. BioMarin Genetic Disorders Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. BioMarin Genetic Disorders Drug Product Portfolio Table 103. BioMarin Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Genetic Disorders Drug Distributors List Table 107. Genetic Disorders Drug Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Genetic Disorders Drug Product Image Figure 2. Global Genetic Disorders Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genetic Disorders Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Genetic Disorders Drug Sales (2021-2032) & (W Units) Figure 5. Global Genetic Disorders Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Genetic Disorders Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Duchenne Muscular Dystrophy (DMD) Image Figure 9. Cystic Fibrosis (CF) Image Figure 10. Lysosomal Storage Disease (LSD) Image Figure 11. Paroxysmal Nocturnal Hemoglobinuria (PNH) Image Figure 12. Global Genetic Disorders Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Genetic Disorders Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Genetic Disorders Drug Sales Market Share by Type (2021-2032) Figure 15. Global Genetic Disorders Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Genetic Disorders Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Genetic Disorders Drug Revenue Market Share by Type (2021-2032) Figure 18. Clinic Image Figure 19. Hospital Image Figure 20. Global Genetic Disorders Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Genetic Disorders Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Genetic Disorders Drug Sales Market Share by Application (2021-2032) Figure 23. Global Genetic Disorders Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Genetic Disorders Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Genetic Disorders Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 27. North America Genetic Disorders Drug Sales Market Share by Country (2021-2032) Figure 28. U.S. Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 29. Canada Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Mexico Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Europe Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Europe Genetic Disorders Drug Sales Market Share by Country (2021-2032) Figure 33. Germany Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. France Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. U.K. Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Italy Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Netherlands Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Asia Pacific Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Asia Pacific Genetic Disorders Drug Sales Market Share by Country (2021-2032) Figure 40. China Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Japan Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. South Korea Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Southeast Asia Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. India Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Australia Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South America, Middle East and Africa Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South America, Middle East and Africa Genetic Disorders Drug Sales Market Share by Country (2021-2032) Figure 48. Brazil Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South Africa Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Saudi Arabia Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Turkey Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Argentina Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. UAE Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Egypt Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Chile Genetic Disorders Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Global Genetic Disorders Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Genetic Disorders Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Genetic Disorders Drug Revenue (2021-2032) & (US$ Million) Figure 59. North America Genetic Disorders Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Genetic Disorders Drug Revenue (2021-2032) & (US$ Million) Figure 61. Europe Genetic Disorders Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Genetic Disorders Drug Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Genetic Disorders Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Genetic Disorders Drug Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Genetic Disorders Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Genetic Disorders Drug Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Genetic Disorders Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Duchenne Muscular Dystrophy (DMD)
  • Cystic Fibrosis (CF)
  • Lysosomal Storage Disease (LSD)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
Applications
  • Clinic
  • Hospital
Companies covered
  • Takeda
  • Sanofi
  • Pfizer
  • Amgen
  • Vertex
  • Sarepta
  • GW Pharmaceuticals
  • BioMarin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Genetic Disorders Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Genetic Disorders Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Genetic Disorders Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Genetic Disorders Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Genetic Disorders Drug Market Dynamics
  1. 2.1 Genetic Disorders Drug Industry Trends
  2. 2.2 Genetic Disorders Drug Industry Drivers
  3. 2.3 Genetic Disorders Drug Industry Opportunities and Challenges
  4. 2.4 Genetic Disorders Drug Industry Restraints
3 Genetic Disorders Drug Market by Manufacturers
  1. 3.1 Global Genetic Disorders Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Genetic Disorders Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Genetic Disorders Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Genetic Disorders Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Genetic Disorders Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Genetic Disorders Drug Manufacturers, Product Type & Application
  7. 3.7 Global Genetic Disorders Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Genetic Disorders Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Genetic Disorders Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Genetic Disorders Drug Tier 1, Tier 2, and Tier 3
4 Genetic Disorders Drug Market by Type
  1. 4.1 Genetic Disorders Drug Type Introduction
  2. 4.1.1 Duchenne Muscular Dystrophy (DMD)
  3. 4.1.2 Cystic Fibrosis (CF)
  4. 4.1.3 Lysosomal Storage Disease (LSD)
  5. 4.1.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
  6. 4.2 Global Genetic Disorders Drug Sales by Type
  7. 4.2.1 Global Genetic Disorders Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Genetic Disorders Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Genetic Disorders Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Genetic Disorders Drug Revenue by Type
  11. 4.3.1 Global Genetic Disorders Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Genetic Disorders Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Genetic Disorders Drug Revenue Market Share by Type (2021-2032)
5 Genetic Disorders Drug Market by Application
  1. 5.1 Genetic Disorders Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.2 Global Genetic Disorders Drug Sales by Application
  5. 5.2.1 Global Genetic Disorders Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Genetic Disorders Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Genetic Disorders Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Genetic Disorders Drug Revenue by Application
  9. 5.3.1 Global Genetic Disorders Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Genetic Disorders Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Genetic Disorders Drug Revenue Market Share by Application (2021-2032)
6 Global Genetic Disorders Drug Sales by Region
  1. 6.1 Global Genetic Disorders Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Genetic Disorders Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Genetic Disorders Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Genetic Disorders Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Genetic Disorders Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Genetic Disorders Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Genetic Disorders Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Genetic Disorders Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Genetic Disorders Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Genetic Disorders Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Genetic Disorders Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Genetic Disorders Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Genetic Disorders Drug Revenue by Region
  1. 7.1 Global Genetic Disorders Drug Revenue by Region
  2. 7.1.1 Global Genetic Disorders Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Genetic Disorders Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Genetic Disorders Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Genetic Disorders Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Genetic Disorders Drug Revenue (2021-2032)
  8. 7.2.2 North America Genetic Disorders Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Genetic Disorders Drug Revenue (2021-2032)
  11. 7.3.2 Europe Genetic Disorders Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Genetic Disorders Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Genetic Disorders Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Genetic Disorders Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Genetic Disorders Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Genetic Disorders Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Genetic Disorders Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Genetic Disorders Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Genetic Disorders Drug Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Genetic Disorders Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Genetic Disorders Drug Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Genetic Disorders Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Genetic Disorders Drug Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 Vertex
  26. 8.5.1 Vertex Company Information
  27. 8.5.2 Vertex Business Overview
  28. 8.5.3 Vertex Genetic Disorders Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Vertex Genetic Disorders Drug Product Portfolio
  30. 8.5.5 Vertex Recent Developments
  31. 8.6 Sarepta
  32. 8.6.1 Sarepta Company Information
  33. 8.6.2 Sarepta Business Overview
  34. 8.6.3 Sarepta Genetic Disorders Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sarepta Genetic Disorders Drug Product Portfolio
  36. 8.6.5 Sarepta Recent Developments
  37. 8.7 GW Pharmaceuticals
  38. 8.7.1 GW Pharmaceuticals Company Information
  39. 8.7.2 GW Pharmaceuticals Business Overview
  40. 8.7.3 GW Pharmaceuticals Genetic Disorders Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GW Pharmaceuticals Genetic Disorders Drug Product Portfolio
  42. 8.7.5 GW Pharmaceuticals Recent Developments
  43. 8.8 BioMarin
  44. 8.8.1 BioMarin Company Information
  45. 8.8.2 BioMarin Business Overview
  46. 8.8.3 BioMarin Genetic Disorders Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BioMarin Genetic Disorders Drug Product Portfolio
  48. 8.8.5 BioMarin Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Genetic Disorders Drug Value Chain Analysis
  2. 9.1.1 Genetic Disorders Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Genetic Disorders Drug Production Mode & Process
  6. 9.2 Genetic Disorders Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Genetic Disorders Drug Distributors
  9. 9.2.3 Genetic Disorders Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst